Mecapharma

What Mecapharma does

Mecapharma is a Lebanon-headquartered pharmaceutical services company that operates as a 'One Stop Shop' business platform for American and European pharmaceutical companies seeking to commercialise in the MENA region without establishing local subsidiaries. The firmographic record places founding around 2014 with 11-50 employees, and the group is structured across three legal entities: MECAPHARMA SAL (offshore) as the headquarters and mother company directing group-wide operations and training; MECAPHARMA CV, a Netherlands-registered Market Authorization Holder ensuring EMA compliance for proprietary products; and MECAPHARMA SAL, the Lebanese operating entity regulated by the Lebanese Ministry of Health. The company maintains an established multinational distribution network across 14+ markets including Saudi Arabia, the UAE, Kuwait, Qatar, Oman, Bahrain, Iraq, Jordan, Egypt, Turkey, Libya, Tunisia, Algeria, Morocco, and Mexico.

The service offering spans product registration with each country's Ministry of Health, dedicated hospital market development through tailored in-house business units, national and regional tender participation, NPU (Named Patient Use) sales, promotion and sales through dedicated field forces, medical information services, and a rare/challenging disorders program that imports US/EU-available therapies into MENA on NPU basis and then registers them for continuity. Pharmacovigilance and quality assurance activities follow both Market Authorization Holder requirements and country-of-distribution regulations, with regular staff training on EU and regional guidelines. The technical backbone is regulatory and procedural rather than software-driven, grounded in two decades of accumulated country-specific licensing, reimbursement, and distribution know-how across non-harmonised MENA jurisdictions.

Commercially, Mecapharma combines transaction-based revenue from product sales margins and registration-related fees, licensing/royalty income from MAH services applied to proprietary products, and professional services revenue from medical information and PV support. Go-to-market is sales-led and relationship-driven at principal level; each business unit is staffed for a specific principal and market posture, and pricing is quote-based and not publicly disclosed. The company is privately held with no external investors, funding rounds, or acquisitions identified, and revenue concentration is structurally elevated because the exclusive-agent model ties the platform to a limited number of named pharmaceutical principals.

Name

Mecapharma

Legal name

MECAPHARMA SAL (offshore)

Website

https://mecapharma.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Mecapharma is a Lebanon-headquartered pharmaceutical services platform that registers, sells, and provides pharmacovigilance and medical information support for American and European pharmaceutical products across 14+ MENA and Latin American markets under FDA/EMA compliance standards.

Ownership category

akta.pro rank

Product category

Pharmaceutical Commercialization Services

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Services-Management Services (8741), Services-Health Services (8000)

akta.pro primary industry

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ)

Keywords

• Pharmaceutical distribution services
• Pharmacovigilance compliance
• Product registration services
• Medical information services
• Market authorization holding

Headquarters

HQ city

Beirut

HQ country

Lebanon

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Others

Revenue model

1. Pharmaceutical Product Registration and Sales: Mecapharma acts as sole exclusive agent representing European and American pharmaceutical companies, registering their products in MENA countries and selling them at market agreed/registered prices. The company earns revenue through product sales margins, registration fees, and potentially tender participation fees.
2. Market Authorization Holder Services: MECAPHARMA CV represents Mecapharma SAL as Market Authorization Holder of proprietary products, fulfilling EMA requirements and guidelines.
3. Medical Information and PV Services: Providing medical information to health professionals and following up on pharmacovigilance activities including adverse event reporting and monthly reconciliation as per EU & regional guidelines.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels1 record

Core offering

Mecapharma is a B2B pharmaceutical services platform that acts as sole exclusive agent for American and European pharmaceutical companies in the MENA region, delivering end-to-end commercialization including product registration with local health authorities, promotion, sales via dedicated field force and national distributors, national and regional tender participation, Named Patient Use (NPU) sales, and pharmacovigilance and medical information services. The group also operates as Market Authorization Holder for proprietary products through its Dutch EMA-aligned entity, and runs a dedicated program bringing treatments for rare and challenging disorders to the region.

Product overview

MECAPHARMA® is a pharmaceutical services company operating as a unified business platform composed of three subsidiaries: MECAPHARMA SAL (offshore) as the headquarters conducting all group operations and training, MECAPHARMA CV serving as the EMA-compliant Market Authorization Holder for proprietary products, and MECAPHARMA SAL as the local Lebanese operating entity. The company acts as sole exclusive agent for European and American pharmaceutical companies in the MENA region, offering an integrated suite of services including product registration, pharmacovigilance and quality assurance, medical information support, tender participation, NPU sales, field force training, and product promotion and sales. The platform also specializes in bringing treatments for rare and challenging disorders to the MENA market through its dedicated disorder program. The company adapts its business model by creating dedicated business units tailored to specific partner requirements and market conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• Business Platform / One Stop Shop End-to-end pharmaceutical commercialization platform dedicated to establishing and developing hospital market presence on behalf of pharmaceutical companies that have neither scientific office nor subsidiary in the MENA region. Adapts to growing business needs and abides by an ethical code of conduct while respecting the legal requirements of represented partners.
• Product Registration Services Registers American and European pharmaceutical products within MENA countries according to respective MOH country requirements and legislations, enabling legal commercialization.
• Pharmacovigilance and Quality Assurance Services Implements pharmacovigilance and quality assurance activities per FDA/EMA and regional guidelines, including adverse event reporting, monthly reconciliation, and regular training of personnel and network collaborators.
• Medical Information Services Provides ethical medical information upon request of health professionals, answering queries and liaising with the pharmaceutical companies represented to ensure appropriate use of products.
• Rare and Challenging Disorders Treatment Program Brings US and/or EU-available treatments for challenging and/or rare disorders to the MENA region on a Named Patient Use basis, then registers them with respective MENA health authorities to ensure continuity of treatment and patient compliance.
• Tender Participation Services Participates in national and regional tenders on behalf of partner pharmaceutical companies to secure institutional and government procurement of registered products.
• Named Patient Use (NPU) Sales Rapidly initiates Named Patient Use sales whenever possible, allowing access to pharmaceutical products before full registration in a given MENA market.
• Market Authorization Holder Services (MECAPHARMA CV) Through its Dutch-based entity MECAPHARMA CV, Mecapharma acts as Market Authorization Holder for MECAPHARMA proprietary products, fulfilling all EMA requirements and guidelines.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/mecapharma-group
• Xx.com/mecapharma

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mecapharma